{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:10:08Z","timestamp":1791580208734,"version":"4.3.4"},"reference-count":295,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41571-025-01084-0","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:28:23Z","timestamp":1762871303000},"page":"40-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The biology and therapeutic implications of heterogeneity in Barrett oesophagus and oesophageal adenocarcinoma"],"prefix":"10.1038","volume":"23","author":[{"given":"Dylan P.","family":"McClurg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1584-8026","authenticated-orcid":false,"given":"Sally","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3434-3568","authenticated-orcid":false,"given":"Rebecca C.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4513-4964","authenticated-orcid":false,"given":"Christopher M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"1084_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan, E. et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 163, 649\u2013658.e2 (2022).","journal-title":"Gastroenterology"},{"key":"1084_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.29497","volume":"6","author":"GM Rodriguez","year":"2023","unstructured":"Rodriguez, G. M. et al. Trends in epidemiology of esophageal cancer in the US, 1975\u20132018. JAMA Netw. Open\u00a06, e2329497 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1084_CR3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/cncr.27834","volume":"119","author":"C Hur","year":"2013","unstructured":"Hur, C. et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119, 1149\u20131158 (2013).","journal-title":"Cancer"},{"key":"1084_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcmgh.2014.10.001","volume":"1","author":"SA McDonald","year":"2015","unstructured":"McDonald, S. A., Graham, T. A., Lavery, D. L., Wright, N. A. & Jansen, M. The Barrett\u2019s gland in phenotype space. Cell Mol. Gastroenterol. Hepatol. 1, 41\u201354 (2015).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1084_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41572-019-0086-z","volume":"5","author":"Y Peters","year":"2019","unstructured":"Peters, Y. et al. Barrett oesophagus. Nat. Rev. Dis. Primers\u00a05, 35 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1084_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/1055-9965.EPI-20-0944","volume":"30","author":"DC Codipilly","year":"2021","unstructured":"Codipilly, D. C. et al. Epidemiology and outcomes of young-onset esophageal adenocarcinoma: an analysis from a population-based database. Cancer Epidemiol. Biomark. Prev. 30, 142\u2013149 (2021).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1084_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrgastro.2014.69","volume":"11","author":"R Anaparthy","year":"2014","unstructured":"Anaparthy, R. & Sharma, P. Progression of Barrett oesophagus: role of endoscopic and histological predictors. Nat. Rev. Gastroenterol. Hepatol. 11, 525\u2013534 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1084_CR8","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1056\/NEJMoa1103042","volume":"365","author":"F Hvid-Jensen","year":"2011","unstructured":"Hvid-Jensen, F., Pedersen, L., Drewes, A. M., S\u00f8rensen, H. T. & Funch-Jensen, P. Incidence of adenocarcinoma among patients with Barrett\u2019s esophagus. N. Engl. J. Med. 365, 1375\u20131383 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1126\/science.abd1449","volume":"373","author":"K Nowicki-Osuch","year":"2021","unstructured":"Nowicki-Osuch, K. et al. Molecular phenotyping reveals the identity of Barrett\u2019s esophagus and its malignant transition. Science 373, 760\u2013767 (2021).","journal-title":"Science"},{"key":"1084_CR10","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1136\/gutjnl-2020-321598","volume":"70","author":"K Curtius","year":"2020","unstructured":"Curtius, K., Rubenstein, J. H., Chak, A. & Inadomi, J. M. Computational modelling suggests that Barrett\u2019s oesophagus may be the precursor of all oesophageal adenocarcinomas. Gut 70, 1435\u20131440 (2020).","journal-title":"Gut"},{"key":"1084_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/gutjnl-2020-321089","volume":"70","author":"E Morgan","year":"2021","unstructured":"Morgan, E. et al. International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. Gut 70, 234\u2013242 (2021).","journal-title":"Gut"},{"key":"1084_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021495","volume":"8","author":"JH Kauppila","year":"2018","unstructured":"Kauppila, J. H., Mattsson, F., Brusselaers, N. & Lagergren, J. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. BMJ Open 8, e021495 (2018).","journal-title":"BMJ Open"},{"key":"1084_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","volume":"8","author":"JV Reynolds","year":"2023","unstructured":"Reynolds, J. V. et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol. Hepatol. 8, 1015\u20131027 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1084_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner, J. et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N. Engl. J. Med. 392, 323\u2013335 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1254","volume":"11","author":"EO Then","year":"2020","unstructured":"Then, E. O. et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J. Oncol. 11, 55\u201364 (2020).","journal-title":"World J. Oncol."},{"key":"1084_CR16","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191\u20131203 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannova","year":"2022","unstructured":"Obermannova, R. et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 992\u20131004 (2022).","journal-title":"Ann. Oncol."},{"key":"1084_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"1084_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1084_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat. Rev. Immunol. 25, 353\u2013369 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1084_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1084_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"1084_CR23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41556-018-0236-7","volume":"20","author":"DA Lawson","year":"2018","unstructured":"Lawson, D. A., Kessenbrock, K., Davis, R. T., Pervolarakis, N. & Werb, Z. Tumour heterogeneity and metastasis at single-cell resolution. Nat. Cell Biol. 20, 1349\u20131360 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1084_CR24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41588-018-0331-5","volume":"51","author":"AM Frankell","year":"2019","unstructured":"Frankell, A. M. et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat. Genet. 51, 506\u2013516 (2019).","journal-title":"Nat. Genet."},{"key":"1084_CR25","doi-asserted-by":"publisher","first-page":"110224","DOI":"10.1016\/j.radonc.2024.110224","volume":"195","author":"DP McClurg","year":"2024","unstructured":"McClurg, D. P., Sanghera, C., Mukherjee, S., Fitzgerald, R. C. & Jones, C. M. A systematic review of circulating predictive and prognostic biomarkers to aid the personalised use of radiotherapy in the radical treatment of patients with oesophageal cancer. Radiother. Oncol. 195, 110224 (2024).","journal-title":"Radiother. Oncol."},{"key":"1084_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bjc.2017.21","volume":"116","author":"T Crosby","year":"2017","unstructured":"Crosby, T. et al. Long-term results and recurrence patterns from SCOPE-1: a phase II\/III randomised trial of definitive chemoradiotherapy +\/\u2212 cetuximab in oesophageal cancer. Br. J. Cancer 116, 709\u2013716 (2017).","journal-title":"Br. J. Cancer"},{"key":"1084_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2021.05.020","volume":"153","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee, S. et al. Oxaliplatin\/capecitabine or carboplatin\/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. Eur. J. Cancer 153, 153\u2013161 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1084_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/14712598.2024.2395921","volume":"24","author":"I Nakayama","year":"2024","unstructured":"Nakayama, I. & Shitara, K. The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma. Expert Opin. Biol. Ther. 24, 903\u2013915 (2024).","journal-title":"Expert Opin. Biol. Ther."},{"key":"1084_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrc2773","volume":"10","author":"BJ Reid","year":"2010","unstructured":"Reid, B. J., Li, X., Galipeau, P. C. & Vaughan, T. L. Barrett\u2019s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat. Rev. Cancer 10, 87\u2013101 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"1084_CR30","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/gutjnl-2011-301174","volume":"61","author":"AM Nicholson","year":"2012","unstructured":"Nicholson, A. M. et al. Barrett\u2019s metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. Gut 61, 1380\u20131389 (2012).","journal-title":"Gut"},{"key":"1084_CR31","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2021.12.271","volume":"162","author":"JA Evans","year":"2022","unstructured":"Evans, J. A. et al. Clonal transitions and phenotypic evolution in Barrett\u2019s esophagus. Gastroenterology 162, 1197\u2013209.e13 (2022).","journal-title":"Gastroenterology"},{"key":"1084_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1476-5586(04)80089-7","volume":"6","author":"JJ Going","year":"2004","unstructured":"Going, J. J. et al. Zoning of mucosal phenotype, dysplasia, and telomerase activity measured by telomerase repeat assay protocol in Barrett\u2019s esophagus. Neoplasia 6, 85\u201392 (2004).","journal-title":"Neoplasia"},{"key":"1084_CR33","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJM197608262950904","volume":"295","author":"A Paull","year":"1976","unstructured":"Paull, A. et al. The histologic spectrum of Barrett\u2019s esophagus. N. Engl. J. Med. 295, 476\u2013480 (1976).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR34","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1097\/00000478-200109000-00010","volume":"25","author":"PT Chandrasoma","year":"2001","unstructured":"Chandrasoma, P. T. et al. Distribution and significance of epithelial types in columnar-lined esophagus. Am. J. Surg. Pathol. 25, 1188\u20131193 (2001).","journal-title":"Am. J. Surg. Pathol."},{"key":"1084_CR35","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/j.gastro.2017.09.046","volume":"154","author":"M Quante","year":"2018","unstructured":"Quante, M., Graham, T. A. & Jansen, M. Insights into the pathophysiology of esophageal adenocarcinoma. Gastroenterology 154, 406\u2013420 (2018).","journal-title":"Gastroenterology"},{"key":"1084_CR36","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/gutjnl-2013-306508","volume":"63","author":"DL Lavery","year":"2014","unstructured":"Lavery, D. L. et al. The stem cell organisation, and the proliferative and gene expression profile of Barrett\u2019s epithelium, replicates pyloric-type gastric glands. Gut 63, 1854\u20131863 (2014).","journal-title":"Gut"},{"key":"1084_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cgh.2018.08.066","volume":"17","author":"EC Lin","year":"2019","unstructured":"Lin, E. C., Holub, J., Lieberman, D. & Hur, C. Low prevalence of suspected Barrett\u2019s esophagus in patients with gastroesophageal reflux disease without alarm symptoms. Clin. Gastroenterol. Hepatol. 17, 857\u2013863 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1084_CR38","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/gut.2007.143339","volume":"57","author":"SJ Leedham","year":"2008","unstructured":"Leedham, S. J. et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett\u2019s oesophagus. Gut 57, 1041\u20131048 (2008).","journal-title":"Gut"},{"key":"1084_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jcmgh.2017.07.005","volume":"4","author":"Furstenberg","year":"2017","unstructured":"Furstenberg et al. Porcine esophageal submucosal gland culture model shows capacity for proliferation and differentiation. Cell. Mol. Gastroenterol. Hepatol. 4, 385\u2013404 (2017).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"1084_CR40","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11605-007-0174-3","volume":"11","author":"Y Hu","year":"2007","unstructured":"Hu, Y. et al. The pathogenesis of Barrett\u2019s esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells. J. Gastrointest. Surg. 11, 827\u2013834 (2007).","journal-title":"J. Gastrointest. Surg."},{"key":"1084_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2011.12.004","volume":"21","author":"M Quante","year":"2012","unstructured":"Quante, M. et al. Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett\u2019s-like metaplasia. Cancer Cell 21, 36\u201351 (2012).","journal-title":"Cancer Cell"},{"key":"1084_CR42","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.cell.2011.05.026","volume":"145","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. Residual embryonic cells as precursors of a Barrett\u2019s-like metaplasia. Cell 145, 1023\u20131023 (2011).","journal-title":"Cell"},{"key":"1084_CR43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature24269","volume":"550","author":"M Jiang","year":"2017","unstructured":"Jiang, M. et al. Transitional basal cells at the squamous\u2013columnar junction generate Barrett\u2019s oesophagus. Nature 550, 529\u2013533 (2017).","journal-title":"Nature"},{"key":"1084_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/scd.2010.0139","volume":"20","author":"L Hutchinson","year":"2010","unstructured":"Hutchinson, L. et al. Human Barrett\u2019s adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. Stem Cell Dev. 20, 11\u201317 (2010).","journal-title":"Stem Cell Dev."},{"key":"1084_CR45","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/0016-5085(92)91510-B","volume":"103","author":"AJ Cameron","year":"1992","unstructured":"Cameron, A. J. & Lomboy, C. T. Barrett\u2019s esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 103, 1241\u20131245 (1992).","journal-title":"Gastroenterology"},{"key":"1084_CR46","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/j.devcel.2025.06.034","volume":"60","author":"MK Strasser","year":"2025","unstructured":"Strasser, M. K. et al. Concerted changes in epithelium and stroma: a multi-scale, multi-omics analysis of progression from Barrett\u2019s esophagus to adenocarcinoma. Dev. Cell. 60, 2807\u20132824.e7 (2025).","journal-title":"Dev. Cell."},{"key":"1084_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28237-4","volume":"13","author":"AC Katz-Summercorn","year":"2022","unstructured":"Katz-Summercorn, A. C. et al. Multi-omic cross-sectional cohort study of pre-malignant Barrett\u2019s esophagus reveals early structural variation and retrotransposon activity. Nat. Commun. 13, 1407 (2022).","journal-title":"Nat. Commun."},{"key":"1084_CR48","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/ng.3357","volume":"47","author":"CS Ross-Innes","year":"2015","unstructured":"Ross-Innes, C. S. et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett\u2019s esophagus and esophageal adenocarcinoma. Nat. Genet. 47, 1038\u20131046 (2015).","journal-title":"Nat. Genet."},{"key":"1084_CR49","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/ng.3343","volume":"47","author":"MD Stachler","year":"2015","unstructured":"Stachler, M. D. et al. Paired exome analysis of Barrett\u2019s esophagus and adenocarcinoma. Nat. Genet. 47, 1047\u20131055 (2015).","journal-title":"Nat. Genet."},{"key":"1084_CR50","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/gutjnl-2023-331557","volume":"73","author":"M di Pietro","year":"2024","unstructured":"di Pietro, M. et al. National Institute for health and Care Excellence (NICE) guidance on monitoring and management of Barrett\u2019s oesophagus and stage I oesophageal adenocarcinoma. Gut 73, 897\u2013909 (2024).","journal-title":"Gut"},{"key":"1084_CR51","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/gutjnl-2023-330721","volume":"73","author":"EL Black","year":"2024","unstructured":"Black, E. L. et al. Understanding the malignant potential of gastric metaplasia of the oesophagus and its relevance to Barrett\u2019s oesophagus surveillance: individual-level data analysis. Gut 73, 729\u2013740 (2024).","journal-title":"Gut"},{"key":"1084_CR52","doi-asserted-by":"publisher","first-page":"100980","DOI":"10.1016\/j.xgen.2025.100980","volume":"5","author":"MC Wenzel","year":"2025","unstructured":"Wenzel, M. C. et al. Single-cell analysis of Barrett\u2019s esophagus and carcinoma reveals cell types conferring risk via genetic predisposition. Cell Genom. 5, 100980 (2025).","journal-title":"Cell Genom."},{"key":"1084_CR53","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/1940-6207.CAPR-13-0289","volume":"7","author":"X Li","year":"2014","unstructured":"Li, X. et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett\u2019s esophagus. Cancer Prev. Res. 7, 114\u2013127 (2014).","journal-title":"Cancer Prev. Res."},{"key":"1084_CR54","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41591-020-1033-y","volume":"26","author":"S Killcoyne","year":"2020","unstructured":"Killcoyne, S. et al. Genomic copy number predicts esophageal cancer years before transformation. Nat. Med. 26, 1726\u20131732 (2020).","journal-title":"Nat. Med."},{"key":"1084_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12158","volume":"7","author":"P Martinez","year":"2016","unstructured":"Martinez, P. et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett\u2019s oesophagus. Nat. Commun. 7, 12158 (2016).","journal-title":"Nat. Commun."},{"key":"1084_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39957-6","volume":"14","author":"S Abbas","year":"2023","unstructured":"Abbas, S. et al. Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma. Nat. Commun. 14, 4239 (2023).","journal-title":"Nat. Commun."},{"key":"1084_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29767-7","volume":"13","author":"TG Paulson","year":"2022","unstructured":"Paulson, T. G. et al. Somatic whole genome dynamics of precancer in Barrett\u2019s esophagus reveals features associated with disease progression. Nat. Commun. 13, 2300 (2022).","journal-title":"Nat. Commun."},{"key":"1084_CR58","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/ng1768","volume":"38","author":"CC Maley","year":"2006","unstructured":"Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468\u2013473 (2006).","journal-title":"Nat. Genet."},{"key":"1084_CR59","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1158\/0008-5472.CAN-03-3249","volume":"64","author":"CC Maley","year":"2004","unstructured":"Maley, C. C. et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett\u2019s esophagus. Cancer Res. 64, 3414\u20133427 (2004).","journal-title":"Cancer Res."},{"key":"1084_CR60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/8816","volume":"22","author":"MT Barrett","year":"1999","unstructured":"Barrett, M. T. et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat. Genet. 22, 106\u2013109 (1999).","journal-title":"Nat. Genet."},{"key":"1084_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02621-x","volume":"9","author":"P Martinez","year":"2018","unstructured":"Martinez, P. et al. Evolution of Barrett\u2019s esophagus through space and time at single-crypt and whole-biopsy levels. Nat. Commun. 9, 794 (2018).","journal-title":"Nat. Commun."},{"key":"1084_CR62","doi-asserted-by":"publisher","unstructured":"Bracht, S. A. et al. Mitochondrial clone tracing within spatially intact human tissues. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.07.11.664452 (2025).","DOI":"10.1101\/2025.07.11.664452"},{"key":"1084_CR63","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/1940-6207.CAPR-15-0130","volume":"8","author":"X Li","year":"2015","unstructured":"Li, X. et al. Assessment of esophageal adenocarcinoma risk using somatic chromosome alterations in longitudinal samples in Barrett\u2019s esophagus. Cancer Prev. Res. 8, 845\u2013856 (2015).","journal-title":"Cancer Prev. Res."},{"key":"1084_CR64","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2006.03.018","volume":"245","author":"CC Maley","year":"2007","unstructured":"Maley, C. C. Multistage carcinogenesis in Barrett\u2019s esophagus. Cancer Lett. 245, 22\u201332 (2007).","journal-title":"Cancer Lett."},{"key":"1084_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003553","volume":"9","author":"RL Kostadinov","year":"2013","unstructured":"Kostadinov, R. L. et al. NSAIDs modulate clonal evolution in Barrett\u2019s esophagus. PLoS Genet. 9, e1003553 (2013).","journal-title":"PLoS Genet."},{"key":"1084_CR66","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/ng.2591","volume":"45","author":"AM Dulak","year":"2013","unstructured":"Dulak, A. M. et al. Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478\u2013486 (2013).","journal-title":"Nat. Genet."},{"key":"1084_CR67","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1136\/gutjnl-2015-309642","volume":"65","author":"MR Timmer","year":"2016","unstructured":"Timmer, M. R. et al. Derivation of genetic biomarkers for cancer risk stratification in Barrett\u2019s oesophagus: a prospective cohort study. Gut 65, 1602\u20131610 (2016).","journal-title":"Gut"},{"key":"1084_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41805-6","volume":"14","author":"C Bao","year":"2023","unstructured":"Bao, C. et al. Genomic signatures of past and present chromosomal instability in Barrett\u2019s esophagus and early esophageal adenocarcinoma. Nat. Commun. 14, 6203 (2023).","journal-title":"Nat. Commun."},{"key":"1084_CR69","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ng.3013","volume":"46","author":"JMJ Weaver","year":"2014","unstructured":"Weaver, J. M. J. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837\u2013843 (2014).","journal-title":"Nat. Genet."},{"key":"1084_CR70","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/2159-8290.CD-13-0285","volume":"4","author":"SM Dewhurst","year":"2014","unstructured":"Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4, 175\u2013185 (2014).","journal-title":"Cancer Discov."},{"key":"1084_CR71","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/gutjnl-2024-332095","volume":"74","author":"G Lian","year":"2025","unstructured":"Lian, G. et al. p53 mutation biases squamocolumnar junction progenitor cells towards dysplasia rather than metaplasia in Barrett\u2019s oesophagus. Gut 74, 182\u2013196 (2025).","journal-title":"Gut"},{"key":"1084_CR72","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s43018-024-00876-0","volume":"6","author":"P Ganguli","year":"2025","unstructured":"Ganguli, P. et al. Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer. Nat. Cancer 6, 158\u2013174 (2025).","journal-title":"Nat. Cancer"},{"key":"1084_CR73","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","volume":"52","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat. Genet. 52, 891\u2013897 (2020).","journal-title":"Nat. Genet."},{"key":"1084_CR74","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41586-023-05937-5","volume":"616","author":"J Luebeck","year":"2023","unstructured":"Luebeck, J. et al. Extrachromosomal DNA in the cancerous transformation of Barrett\u2019s oesophagus. Nature 616, 798\u2013805 (2023).","journal-title":"Nature"},{"key":"1084_CR75","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1158\/1078-0432.CCR-22-0445","volume":"28","author":"M Yu","year":"2022","unstructured":"Yu, M. et al. Novel DNA methylation biomarker panel for detection of esophageal adenocarcinoma and high-grade dysplasia. Clin. Cancer Res. 28, 3761\u20133769 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR76","doi-asserted-by":"publisher","first-page":"eaao5848","DOI":"10.1126\/scitranslmed.aao5848","volume":"10","author":"HR Moinova","year":"2018","unstructured":"Moinova, H. R. et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett\u2019s esophagus. Sci. Transl Med. 10, eaao5848 (2018).","journal-title":"Sci. Transl Med."},{"key":"1084_CR77","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1093\/carcin\/bgt286","volume":"34","author":"E Xu","year":"2013","unstructured":"Xu, E. et al. Genome-wide methylation analysis shows similar patterns in Barrett\u2019s esophagus and esophageal adenocarcinoma. Carcinogenesis 34, 2750\u20132756 (2013).","journal-title":"Carcinogenesis"},{"key":"1084_CR78","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1053\/j.gastro.2020.01.044","volume":"158","author":"S Jammula","year":"2020","unstructured":"Jammula, S. et al. Identification of subtypes of Barrett\u2019s esophagus and esophageal adenocarcinoma based on DNA methylation profiles and integration of transcriptome and genome data. Gastroenterology 158, 1682\u20131697.e1 (2020).","journal-title":"Gastroenterology"},{"key":"1084_CR79","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/carcin\/bgw018","volume":"37","author":"L Krause","year":"2016","unstructured":"Krause, L. et al. Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis 37, 356\u2013365 (2016).","journal-title":"Carcinogenesis"},{"key":"1084_CR80","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/gutjnl-2017-314544","volume":"68","author":"M Yu","year":"2019","unstructured":"Yu, M. et al. Subtypes of Barrett\u2019s oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut 68, 389\u2013399 (2019).","journal-title":"Gut"},{"key":"1084_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001356","volume":"7","author":"H Alvarez","year":"2011","unstructured":"Alvarez, H. et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLOS Genet. 7, e1001356 (2011).","journal-title":"PLOS Genet."},{"key":"1084_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-7-75","volume":"7","author":"E Smith","year":"2008","unstructured":"Smith, E. et al. Similarity of aberrant DNA methylation in Barrett\u2019s esophagus and esophageal adenocarcinoma. Mol. Cancer 7, 75 (2008).","journal-title":"Mol. Cancer"},{"key":"1084_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0273-7","volume":"8","author":"AM Kaz","year":"2016","unstructured":"Kaz, A. M. et al. Global DNA methylation patterns in Barrett\u2019s esophagus, dysplastic Barrett\u2019s, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use. Clin. Epigenet. 8, 111 (2016).","journal-title":"Clin. Epigenet."},{"key":"1084_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004919","volume":"12","author":"K Curtius","year":"2016","unstructured":"Curtius, K. et al. A molecular clock infers heterogeneous tissue age among patients with Barrett\u2019s esophagus. PLoS Comput. Biol. 12, e1004919 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"1084_CR85","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2217\/epi-2023-0214","volume":"15","author":"T Shijimaya","year":"2023","unstructured":"Shijimaya, T. et al. Microarchitectures of Barrett\u2019s esophagus associated with DNA methylation status. Epigenomics 15, 759\u2013767 (2023).","journal-title":"Epigenomics"},{"key":"1084_CR86","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1101\/gr.243345.118","volume":"29","author":"C Rogerson","year":"2019","unstructured":"Rogerson, C. et al. Identification of a primitive intestinal transcription factor network shared between esophageal adenocarcinoma and its precancerous precursor state. Genome Res. 29, 723\u2013736 (2019).","journal-title":"Genome Res."},{"key":"1084_CR87","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57189","volume":"9","author":"C Rogerson","year":"2020","unstructured":"Rogerson, C., Ogden, S., Britton, E., Ang, Y. & Sharrocks, A. D. Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma. eLife 9, e57189 (2020).","journal-title":"eLife"},{"key":"1084_CR88","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/genes13071215","volume":"13","author":"J Moore","year":"2022","unstructured":"Moore, J. et al. Pilot study showing feasibility of phosphoproteomic profiling of pathway-level molecular alterations in Barrett\u2019s esophagus. Genes 13, 1215 (2022).","journal-title":"Genes"},{"key":"1084_CR89","doi-asserted-by":"publisher","first-page":"874255","DOI":"10.3389\/fimmu.2022.874255","volume":"13","author":"S Sundaram","year":"2022","unstructured":"Sundaram, S. et al. Deciphering the immune complexity in esophageal adenocarcinoma and pre-cancerous lesions with sequential multiplex immunohistochemistry and sparse subspace clustering approach. Front. Immunol. 13, 874255 (2022).","journal-title":"Front. Immunol."},{"key":"1084_CR90","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1158\/2159-8290.CD-22-0824","volume":"13","author":"K Nowicki-Osuch","year":"2023","unstructured":"Nowicki-Osuch, K. et al. Single-cell RNA sequencing unifies developmental programs of esophageal and gastric intestinal metaplasia. Cancer Discov. 13, 1346\u20131363 (2023).","journal-title":"Cancer Discov."},{"key":"1084_CR91","doi-asserted-by":"publisher","first-page":"107628","DOI":"10.1016\/j.celrep.2020.107628","volume":"31","author":"S Davidson","year":"2020","unstructured":"Davidson, S. et al. Single-cell RNA sequencing reveals a dynamic stromal niche that supports tumor growth. Cell Rep. 31, 107628 (2020).","journal-title":"Cell Rep."},{"key":"1084_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033899","volume":"7","author":"A Lind","year":"2012","unstructured":"Lind, A. et al. The immune cell composition in Barrett\u2019s metaplastic tissue resembles that in normal duodenal tissue. PLoS ONE 7, e33899 (2012).","journal-title":"PLoS ONE"},{"key":"1084_CR93","doi-asserted-by":"publisher","unstructured":"Lin M. L. et al. Alterations of the composition and spatial organization of the microenvironment following non-dysplastic Barrett\u2019s esophagus through progression to cancer. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.06.09.657642 (2025).","DOI":"10.1101\/2025.06.09.657642"},{"key":"1084_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-074962","volume":"385","author":"N Deboever","year":"2024","unstructured":"Deboever, N., Jones, C. M., Yamashita, K., Ajani, J. A. & Hofstetter, W. L. Advances in diagnosis and management of cancer of the esophagus. BMJ 385, e074962 (2024).","journal-title":"BMJ"},{"key":"1084_CR95","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur, A., Gibson, M. K., Jobe, B. A. & Luketich, J. D. Oesophageal carcinoma. Lancet 381, 400\u2013412 (2013).","journal-title":"Lancet"},{"key":"1084_CR96","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41588-019-0551-3","volume":"52","author":"A Noorani","year":"2020","unstructured":"Noorani, A. et al. Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nat. Genet. 52, 74\u201383 (2020).","journal-title":"Nat. Genet."},{"key":"1084_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11111","volume":"7","author":"JM Findlay","year":"2016","unstructured":"Findlay, J. M. et al. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat. Commun. 7, 11111 (2016).","journal-title":"Nat. Commun."},{"key":"1084_CR98","doi-asserted-by":"publisher","first-page":"114981","DOI":"10.1016\/j.celrep.2024.114981","volume":"43","author":"Sluis","year":"2024","unstructured":"Sluis et al. Karyotype evolution in response to chemoradiotherapy and upon recurrence of esophageal adenocarcinomas. Cell Rep. 43, 114981 (2024).","journal-title":"Cell Rep."},{"key":"1084_CR99","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/2159-8290.CD-15-0412","volume":"5","author":"N Murugaesu","year":"2015","unstructured":"Murugaesu, N. et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 5, 821\u2013831 (2015).","journal-title":"Cancer Discov."},{"key":"1084_CR100","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s43018-025-00955-w","volume":"6","author":"M Barroux","year":"2025","unstructured":"Barroux, M. et al. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma. Nat. Cancer 6, 820\u2013837 (2025).","journal-title":"Nat. Cancer"},{"key":"1084_CR101","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"The Cancer Genome Atlas Research Network.","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169\u2013175 (2017).","journal-title":"Nature"},{"key":"1084_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-019-0476-9","volume":"12","author":"F Newell","year":"2019","unstructured":"Newell, F. et al. Complex structural rearrangements are present in high-grade dysplastic Barrett\u2019s oesophagus samples. BMC Med. Genom. 12, 31 (2019).","journal-title":"BMC Med. Genom."},{"key":"1084_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6224","volume":"5","author":"K Nones","year":"2014","unstructured":"Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5, 5224 (2014).","journal-title":"Nat. Commun."},{"key":"1084_CR104","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/SLA.0000000000006363","volume":"281","author":"M Nakauchi","year":"2025","unstructured":"Nakauchi, M. et al. Genomic landscape of adenocarcinomas across the gastroesophageal junction: moving on from the Siewert classification. Ann. Surg. 281, 989\u2013996 (2025).","journal-title":"Ann. Surg."},{"key":"1084_CR105","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/ng.3659","volume":"48","author":"M Secrier","year":"2016","unstructured":"Secrier, M. et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat. Genet. 48, 1131\u20131141 (2016).","journal-title":"Nat. Genet."},{"key":"1084_CR106","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/ng.2760","volume":"45","author":"TI Zack","year":"2013","unstructured":"Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134\u20131140 (2013).","journal-title":"Nat. Genet."},{"key":"1084_CR107","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"1084_CR108","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s42003-018-0182-8","volume":"1","author":"JY Dai","year":"2018","unstructured":"Dai, J. Y. et al. Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Commun. Biol. 1, 174 (2018).","journal-title":"Commun. Biol."},{"key":"1084_CR109","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1136\/gutjnl-2020-322707","volume":"70","author":"D Hao","year":"2020","unstructured":"Hao, D. et al. Integrated genomic profiling and modeling for risk stratification in patients with advanced esophagogastric adenocarcinoma. Gut 70, 2055\u20132065 (2020).","journal-title":"Gut"},{"key":"1084_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38891-x","volume":"14","author":"MM Naeini","year":"2023","unstructured":"Naeini, M. M. et al. Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nat. Commun. 14, 3155 (2023).","journal-title":"Nat. Commun."},{"key":"1084_CR111","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2023.04.035","volume":"165","author":"S Kumar","year":"2023","unstructured":"Kumar, S. et al. Elevated APE1 dysregulates homologous recombination and cell cycle driving genomic evolution, tumorigenesis and chemoresistance in esophageal adenocarcinoma. Gastroenterology 165, 357\u2013373 (2023).","journal-title":"Gastroenterology"},{"key":"1084_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47619-4","volume":"15","author":"AWT Ng","year":"2024","unstructured":"Ng, A. W. T. et al. Disentangling oncogenic amplicons in esophageal adenocarcinoma. Nat. Commun. 15, 4074 (2024).","journal-title":"Nat. Commun."},{"key":"1084_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01362-z","volume":"16","author":"S Brosda","year":"2024","unstructured":"Brosda, S. et al. Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy. Genome Med. 16, 90 (2024).","journal-title":"Genome Med."},{"key":"1084_CR114","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-17-0787","volume":"8","author":"YY Janjigian","year":"2017","unstructured":"Janjigian, Y. Y. et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 8, 49\u201358 (2017).","journal-title":"Cancer Discov."},{"key":"1084_CR115","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","volume":"8","author":"E Pectasides","year":"2017","unstructured":"Pectasides, E. et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov. 8, 37\u201348 (2017).","journal-title":"Cancer Discov."},{"key":"1084_CR116","doi-asserted-by":"publisher","unstructured":"Lawson, N. M. et al. Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2025.02.19.25322558 (2025).","DOI":"10.1101\/2025.02.19.25322558"},{"key":"1084_CR117","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.4161\/epi.6.12.18199","volume":"6","author":"AM Kaz","year":"2011","unstructured":"Kaz, A. M. et al. DNA methylation profiling in Barrett\u2019s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics 6, 1403\u20131412 (2011).","journal-title":"Epigenetics"},{"key":"1084_CR118","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/ijc.25330","volume":"128","author":"Y Hu","year":"2011","unstructured":"Hu, Y. et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int. J. Cancer 128, 132\u2013143 (2011).","journal-title":"Int. J. Cancer"},{"key":"1084_CR119","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/ajcp\/aqx004","volume":"147","author":"M Fassan","year":"2017","unstructured":"Fassan, M. et al. Early miR-223 upregulation in gastroesophageal carcinogenesis. Am. J. Clin. Pathol. 147, 301\u2013308 (2017).","journal-title":"Am. J. Clin. Pathol."},{"key":"1084_CR120","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1158\/1055-9965.EPI-15-0161","volume":"25","author":"J Drahos","year":"2015","unstructured":"Drahos, J. et al. MicroRNA profiles of Barrett\u2019s esophagus and esophageal adenocarcinoma: differences in glandular non-native epithelium. Cancer Epidemiol. Biomark. Prev. 25, 429\u2013437 (2015).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1084_CR121","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/gutjnl-2019-318325","volume":"69","author":"L Chen","year":"2019","unstructured":"Chen, L. et al. Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in esophageal adenocarcinoma. Gut 69, 630\u2013640 (2019).","journal-title":"Gut"},{"key":"1084_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-5165-0","volume":"19","author":"X Guo","year":"2018","unstructured":"Guo, X., Tang, Y. & Zhu, W. Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns. BMC Genom. 19, 769 (2018).","journal-title":"BMC Genom."},{"key":"1084_CR123","doi-asserted-by":"publisher","first-page":"102188","DOI":"10.1016\/j.xcrm.2025.102188","volume":"6","author":"J Yates","year":"2025","unstructured":"Yates, J. et al. Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma. Cell Rep. Med. 6, 102188 (2025).","journal-title":"Cell Rep. Med."},{"key":"1084_CR124","doi-asserted-by":"publisher","first-page":"18589","DOI":"10.1038\/s41598-020-75541-4","volume":"10","author":"J Li","year":"2020","unstructured":"Li, J. et al. Stromal microenvironment promoted infiltration in esophageal adenocarcinoma and squamous cell carcinoma: a multi-cohort gene-based analysis. Sci. Rep. 10, 18589 (2020).","journal-title":"Sci. Rep."},{"key":"1084_CR125","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143888","volume":"6","author":"KH Lagisetty","year":"2021","unstructured":"Lagisetty, K. H. et al. Immune determinants of Barrett\u2019s progression to esophageal adenocarcinoma. JCI Insight 6, e143888 (2021).","journal-title":"JCI Insight"},{"key":"1084_CR126","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.annonc.2020.04.011","volume":"31","author":"S Derks","year":"2020","unstructured":"Derks, S. et al. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann. Oncol. 31, 1011\u20131020 (2020).","journal-title":"Ann. Oncol."},{"key":"1084_CR127","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1074\/mcp.M116.065078","volume":"16","author":"JR O\u2019Neill","year":"2017","unstructured":"O\u2019Neill, J. R. et al. Quantitative shotgun proteomics unveils candidate novel esophageal adenocarcinoma (EAC)-specific proteins. Mol. Cell. Proteom. 16, 1138\u20131150 (2017).","journal-title":"Mol. Cell. Proteom."},{"key":"1084_CR128","doi-asserted-by":"publisher","first-page":"100764","DOI":"10.1016\/j.mcpro.2024.100764","volume":"23","author":"JR O\u2019Neill","year":"2024","unstructured":"O\u2019Neill, J. R. et al. Multi-omic analysis of esophageal adenocarcinoma uncovers candidate therapeutic targets and cancer-selective posttranscriptional regulation. Mol. Cell. Proteom. 23, 100764 (2024).","journal-title":"Mol. Cell. Proteom."},{"key":"1084_CR129","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1021\/acs.jproteome.0c00629","volume":"20","author":"K Weke","year":"2021","unstructured":"Weke, K. et al. MicroPOTS analysis of Barrett\u2019s esophageal cell line models identifies proteomic changes after physiologic and radiation stress. J. Proteome Res. 20, 2195\u20132205 (2021).","journal-title":"J. Proteome Res."},{"key":"1084_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/prca.201800102","volume":"13","author":"SO Bratlie","year":"2019","unstructured":"Bratlie, S. O., Wallenius, V., Edebo, A., F\u00e4ndriks, L. & Casselbrant, A. Proteomic approach to the potential role of angiotensin II in Barrett dysplasia. Proteom. Clin. Appl. 13, e1800102 (2019).","journal-title":"Proteom. Clin. Appl."},{"key":"1084_CR131","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s10120-024-01573-8","volume":"28","author":"H Abe","year":"2024","unstructured":"Abe, H. et al. Expression of therapy target molecules in esophagogastric junction and Barrett\u2019s adenocarcinoma. Gastric Cancer 28, 264\u2013274 (2024).","journal-title":"Gastric Cancer"},{"key":"1084_CR132","first-page":"845","volume":"20","author":"I Gockel","year":"2008","unstructured":"Gockel, I. et al. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol. Rep. 20, 845\u2013850 (2008).","journal-title":"Oncol. Rep."},{"key":"1084_CR133","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/path.4044","volume":"230","author":"AL Paterson","year":"2013","unstructured":"Paterson, A. L. et al. Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. J. Pathol. 230, 118\u2013128 (2013).","journal-title":"J. Pathol."},{"key":"1084_CR134","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1158\/0008-5472.CAN-14-2051","volume":"74","author":"Z Wang","year":"2014","unstructured":"Wang, Z. et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res. 74, 6364\u20136374 (2014).","journal-title":"Cancer Res."},{"key":"1084_CR135","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00262-016-1826-5","volume":"65","author":"F Noble","year":"2016","unstructured":"Noble, F. et al. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol. Immunother. 65, 651\u2013662 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"1084_CR136","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.1007\/s00432-023-04650-0","volume":"149","author":"ACdS Cunha","year":"2023","unstructured":"Cunha, A. C.dS. et al. Dissecting the inflammatory tumor microenvironment of esophageal adenocarcinoma: mast cells and natural killer cells are favorable prognostic factors and associated with less extensive disease. J. Cancer Res. Clin. Oncol. 149, 6917\u20136929 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1084_CR137","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s12094-021-02556-2","volume":"23","author":"M Schoemmel","year":"2021","unstructured":"Schoemmel, M. et al. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus. Clin. Transl Oncol. 23, 1601\u20131610 (2021).","journal-title":"Clin. Transl Oncol."},{"key":"1084_CR138","doi-asserted-by":"publisher","first-page":"822","DOI":"10.21037\/atm-20-151","volume":"8","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients. Ann. Transl Med. 8, 822 (2020).","journal-title":"Ann. Transl Med."},{"key":"1084_CR139","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/jpm12040627","volume":"12","author":"R Haddad","year":"2022","unstructured":"Haddad, R. et al. Tumor lymphocyte infiltration is correlated with a favorable tumor regression grade after neoadjuvant treatment for esophageal adenocarcinoma. J. Person. Med. 12, 627 (2022).","journal-title":"J. Person. Med."},{"key":"1084_CR140","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1158\/0008-5472.CAN-23-0356","volume":"83","author":"G Arbore","year":"2023","unstructured":"Arbore, G. et al. Preexisting immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma. Cancer Res. 83, 2873\u20132888 (2023).","journal-title":"Cancer Res."},{"key":"1084_CR141","doi-asserted-by":"publisher","first-page":"1954807","DOI":"10.1080\/2162402X.2021.1954807","volume":"10","author":"RSA Goedegebuure","year":"2021","unstructured":"Goedegebuure, R. S. A. et al. Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. Oncoimmunology 10, 1954807 (2021).","journal-title":"Oncoimmunology"},{"key":"1084_CR142","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pathol.2016.10.005","volume":"49","author":"AV Stein","year":"2017","unstructured":"Stein A. V. et al. High intratumoural but not peritumoural inflammatory host response is associated with better prognosis in primary resected oesophageal adenocarcinomas. Pathology 49, 30\u201337 (2017).","journal-title":"Pathology"},{"key":"1084_CR143","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/path.5832","volume":"256","author":"TT Soeratram","year":"2021","unstructured":"Soeratram, T. T. et al. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. J. Pathol. 256, 282\u2013296 (2021).","journal-title":"J. Pathol."},{"key":"1084_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06987-y","volume":"20","author":"MP Humphries","year":"2020","unstructured":"Humphries, M. P. et al. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. BMC Cancer 20, 500 (2020).","journal-title":"BMC Cancer"},{"key":"1084_CR145","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","volume":"26","author":"KI Zhou","year":"2020","unstructured":"Zhou, K. I. et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy. Clin. Cancer Res. 26, 6453\u20136463 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR146","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41416-025-03080-8","volume":"133","author":"RC Walker","year":"2025","unstructured":"Walker, R. C. et al. Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinoma. Br. J. Cancer 133, 633\u2013647 (2025).","journal-title":"Br. J. Cancer"},{"key":"1084_CR147","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/path.4467","volume":"235","author":"TJ Underwood","year":"2015","unstructured":"Underwood, T. J. et al. Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. J. Pathol. 235, 466\u2013477 (2015).","journal-title":"J. Pathol."},{"key":"1084_CR148","doi-asserted-by":"publisher","unstructured":"Beernaert, B. et al. Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS\u2013chemokine\u2013myeloid axis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.05.06.652454 (2025).","DOI":"10.1101\/2025.05.06.652454"},{"key":"1084_CR149","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.21873\/anticanres.11107","volume":"36","author":"J Knief","year":"2016","unstructured":"Knief, J. et al. High density of tumor-infiltrating B-Lymphocytes and plasma cells signifies prolonged overall survival in adenocarcinoma of the esophagogastric junction. Anticancer. Res. 36, 5339\u20135345 (2016).","journal-title":"Anticancer. Res."},{"key":"1084_CR150","doi-asserted-by":"publisher","first-page":"72108","DOI":"10.18632\/oncotarget.19437","volume":"8","author":"MC Svensson","year":"2017","unstructured":"Svensson, M. C. et al. The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget 8, 72108\u201372126 (2017).","journal-title":"Oncotarget"},{"key":"1084_CR151","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/bjc.2015.292","volume":"113","author":"W Cao","year":"2015","unstructured":"Cao, W. et al. Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro. Br. J. Cancer 113, 738\u2013746 (2015).","journal-title":"Br. J. Cancer"},{"key":"1084_CR152","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","volume":"60","author":"RF Gabitass","year":"2011","unstructured":"Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A. & Middleton, G. W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 60, 1419\u20131430 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"1084_CR153","doi-asserted-by":"publisher","first-page":"102219","DOI":"10.1016\/j.ctrv.2021.102219","volume":"98","author":"JM Lonie","year":"2021","unstructured":"Lonie, J. M., Barbour, A. P. & Dolcetti, R. Understanding the immuno-biology of oesophageal adenocarcinoma: towards improved therapeutic approaches. Cancer Treat. Rev. 98, 102219 (2021).","journal-title":"Cancer Treat. Rev."},{"key":"1084_CR154","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ejca.2010.09.043","volume":"47","author":"EF Courrech Staal","year":"2011","unstructured":"Courrech Staal, E. F. et al. Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Eur. J. Cancer 47, 375\u2013382 (2011).","journal-title":"Eur. J. Cancer"},{"key":"1084_CR155","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41416-018-0042-9","volume":"118","author":"A Manousopoulou","year":"2018","unstructured":"Manousopoulou, A. et al. Quantitative proteomic profiling of primary cancer-associated fibroblasts in oesophageal adenocarcinoma. Br. J. Cancer 118, 1200\u20131207 (2018).","journal-title":"Br. J. Cancer"},{"key":"1084_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01666-x","volume":"21","author":"W Croft","year":"2022","unstructured":"Croft, W. et al. The single cell transcriptional landscape of esophageal adenocarcinoma and its modulation by neoadjuvant chemotherapy. Mol. Cancer 21, 200 (2022).","journal-title":"Mol. Cancer"},{"key":"1084_CR157","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1055\/a-2176-2440","volume":"55","author":"BLAM Weusten","year":"2023","unstructured":"Weusten, B. L. A. M. et al. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 55, 1124\u20131146 (2023).","journal-title":"Endoscopy"},{"key":"1084_CR158","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1053\/j.gastro.2025.03.021","volume":"169","author":"O Old","year":"2025","unstructured":"Old, O. et al. Barrett\u2019s Oesophagus Surveillance Versus Endoscopy at Need Study (BOSS): a randomized controlled trial. Gastroenterology 169, 1233\u20131243.e8 (2025).","journal-title":"Gastroenterology"},{"key":"1084_CR159","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S2468-1253(25)00160-8","volume":"10","author":"RC Fitzgerald","year":"2025","unstructured":"Fitzgerald, R. C. & Sasieni, P. Lessons learned from the BOSS trial: new directions in Barrett\u2019s oesophagus. Lancet Gastroenterol. Hepatol. 10, 783\u2013785 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1084_CR160","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1158\/1078-0432.CCR-09-2358","volume":"17","author":"BJ Reid","year":"2011","unstructured":"Reid, B. J., Kostadinov, R. & Maley, C. C. New strategies in Barrett\u2019s esophagus integrating clonal evolutionary theory with clinical management. Clin. Cancer Res. 17, 3512\u20133519 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR161","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3390\/diagnostics14182003","volume":"14","author":"S Laun","year":"2024","unstructured":"Laun, S. et al. Analytical validation of Esopredict, an epigenetic prognostic assay for patients with Barrett\u2019s esophagus. Diagnostics 14, 2003 (2024).","journal-title":"Diagnostics"},{"key":"1084_CR162","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.14309\/ajg.0000000000003367","volume":"120","author":"SE Laun","year":"2025","unstructured":"Laun, S. E. et al. Spatiotemporal study of a risk-stratification epigenetic-based biomarker assay in Barrett\u2019s esophagus patients. Am. J. Gastroenterol. 120, 1285\u20131295 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"1084_CR163","doi-asserted-by":"publisher","first-page":"545","DOI":"10.14309\/ajg.0000000000002962","volume":"120","author":"KB Greer","year":"2025","unstructured":"Greer, K. B. et al. Nonendoscopic screening for Barrett\u2019s esophagus and esophageal adenocarcinoma in at-risk veterans. Am. J. Gastroenterol. 120, 545\u2013553 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"1084_CR164","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.gie.2017.07.039","volume":"87","author":"PR Vennalaganti","year":"2018","unstructured":"Vennalaganti, P. R. et al. Increased detection of Barrett\u2019s esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. Gastrointest. Endosc. 87, 348\u2013355 (2018).","journal-title":"Gastrointest. Endosc."},{"key":"1084_CR165","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.gie.2013.05.028","volume":"79","author":"LM Almond","year":"2014","unstructured":"Almond, L. M. et al. Endoscopic Raman spectroscopy enables objective diagnosis of dysplasia in Barrett\u2019s esophagus. Gastrointest. Endosc. 79, 37\u201345 (2014).","journal-title":"Gastrointest. Endosc."},{"key":"1084_CR166","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1053\/j.gastro.2013.11.002","volume":"146","author":"MS Bergholt","year":"2014","unstructured":"Bergholt, M. S. et al. Fiberoptic confocal Raman spectroscopy for real-time in vivo diagnosis of dysplasia in Barrett\u2019s esophagus. Gastroenterology 146, 27\u201332 (2014).","journal-title":"Gastroenterology"},{"key":"1084_CR167","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2017-314953","volume":"68","author":"WB Nagengast","year":"2017","unstructured":"Nagengast, W. B. et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor A. Gut 68, 7\u201310 (2017).","journal-title":"Gut"},{"key":"1084_CR168","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1136\/gutjnl-2020-322945","volume":"70","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Multiplexed endoscopic imaging of Barrett\u2019s neoplasia using targeted fluorescent heptapeptides in a phase 1 proof-of-concept study. Gut 70, 1010\u20131013 (2021).","journal-title":"Gut"},{"key":"1084_CR169","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(20)31099-0","volume":"396","author":"RC Fitzgerald","year":"2020","unstructured":"Fitzgerald, R. C. et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett\u2019s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet 396, 333\u2013344 (2020).","journal-title":"Lancet"},{"key":"1084_CR170","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2468-1253(16)30118-2","volume":"2","author":"CS Ross-Innes","year":"2017","unstructured":"Ross-Innes, C. S. et al. Risk stratification of Barrett\u2019s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol. Hepatol. 2, 23\u201331 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1084_CR171","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.14309\/ajg.0000000000002850","volume":"119","author":"HR Moinova","year":"2024","unstructured":"Moinova, H. R. et al. Multicenter, prospective trial of nonendoscopic biomarker-driven detection of Barrett\u2019s esophagus and esophageal adenocarcinoma. Am. J. Gastroenterol. 119, 2206\u20132214 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"1084_CR172","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/1078-0432.CCR-18-3696","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang, Z. et al. Methylation biomarker panel performance in esophacap cytology samples for diagnosing Barrett\u2019s esophagus: a prospective validation study. Clin. Cancer Res. 25, 2127\u20132135 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR173","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.gie.2021.03.937","volume":"94","author":"PG Iyer","year":"2021","unstructured":"Iyer, P. G. et al. Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett\u2019s esophagus in a multisite case-control study. Gastrointest. Endosc. 94, 498\u2013505 (2021).","journal-title":"Gastrointest. Endosc."},{"key":"1084_CR174","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.14309\/ajg.0000000000000656","volume":"115","author":"PG Iyer","year":"2020","unstructured":"Iyer, P. G. et al. Accurate nonendoscopic detection of Barrett\u2019s esophagus by methylated DNA markers: a multisite case control study. Am. J. Gastroenterol. 115, 1201\u20131209 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"1084_CR175","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1470-2045(21)00667-7","volume":"23","author":"ND Pilonis","year":"2022","unstructured":"Pilonis, N. D. et al. Use of a cytosponge biomarker panel to prioritise endoscopic Barrett\u2019s oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot. Lancet Oncol. 23, 270\u2013278 (2022).","journal-title":"Lancet Oncol."},{"key":"1084_CR176","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(25)01021-9","volume":"406","author":"WK Tan","year":"2025","unstructured":"Tan, W. K. et al. Biomarker risk stratification with capsule sponge in the surveillance of Barrett\u2019s oesophagus: prospective evaluation of UK real-world implementation. Lancet 406, 271\u2013282 (2025).","journal-title":"Lancet"},{"key":"1084_CR177","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.trsl.2017.09.004","volume":"190","author":"E Rumiato","year":"2017","unstructured":"Rumiato, E. et al. Detection of genetic alterations in cfDNA as a possible strategy to monitor the neoplastic progression of Barrett\u2019s esophagus. Transl Res. 190, 16\u201324.e1 (2017).","journal-title":"Transl Res."},{"key":"1084_CR178","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/apt.15235","volume":"49","author":"AT Kunzmann","year":"2019","unstructured":"Kunzmann, A. T. et al. External validation of a model to determine risk of progression of Barrett\u2019s oesophagus to neoplasia. Aliment. Pharm. Ther. 49, 1274\u20131281 (2019).","journal-title":"Aliment. Pharm. Ther."},{"key":"1084_CR179","first-page":"201","volume":"32","author":"H Kuramochi","year":"2008","unstructured":"Kuramochi, H. et al. Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients. Int. J. Oncol. 32, 201\u20138 (2008).","journal-title":"Int. J. Oncol."},{"key":"1084_CR180","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jso.21641","volume":"102","author":"R Langer","year":"2010","unstructured":"Langer, R. et al. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J. Surg. Oncol. 102, 503\u2013508 (2010).","journal-title":"J. Surg. Oncol."},{"key":"1084_CR181","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/sj.bjc.6605686","volume":"102","author":"KR Fareed","year":"2010","unstructured":"Fareed, K. R. et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br. J. Cancer 102, 1600\u20131607 (2010).","journal-title":"Br. J. Cancer"},{"key":"1084_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24232-2","volume":"8","author":"TP MacGregor","year":"2018","unstructured":"MacGregor, T. P. et al. Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma. Sci. Rep. 8, 7265 (2018).","journal-title":"Sci. Rep."},{"key":"1084_CR183","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3390\/antiox11101859","volume":"11","author":"F Ballout","year":"2022","unstructured":"Ballout, F. et al. Targeting NRF2 sensitizes esophageal adenocarcinoma cells to cisplatin through induction of ferroptosis and apoptosis. Antioxidants 11, 1859 (2022).","journal-title":"Antioxidants"},{"key":"1084_CR184","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.3390\/ijms22115547","volume":"22","author":"A-K Eichelmann","year":"2021","unstructured":"Eichelmann, A.-K. et al. Mutant p53 mediates sensitivity to cancer treatment agents in oesophageal adenocarcinoma associated with microRNA and SLC7A11 expression. Int. J. Mol. Sci. 22, 5547 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1084_CR185","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/path.4199","volume":"230","author":"M Aichler","year":"2013","unstructured":"Aichler, M. et al. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J. Pathol. 230, 410\u2013419 (2013).","journal-title":"J. Pathol."},{"key":"1084_CR186","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197610","volume":"13","author":"O Adams","year":"2018","unstructured":"Adams, O. et al. A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas. PLoS ONE 13, e0197610 (2018).","journal-title":"PLoS ONE"},{"key":"1084_CR187","doi-asserted-by":"publisher","first-page":"25897","DOI":"10.18632\/oncotarget.4532","volume":"6","author":"AL Myers","year":"2015","unstructured":"Myers, A. L. et al. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma. Oncotarget 6, 25897\u201325916 (2015).","journal-title":"Oncotarget"},{"key":"1084_CR188","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/bjc.2014.45","volume":"110","author":"GH Bain","year":"2014","unstructured":"Bain, G. H. et al. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. Br. J. Cancer 110, 1525\u20131534 (2014).","journal-title":"Br. J. Cancer"},{"key":"1084_CR189","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtcvs.2015.05.006","volume":"150","author":"Z Wang","year":"2015","unstructured":"Wang, Z. et al. The role of dickkopf-3 overexpression in esophageal adenocarcinoma. J. Thorac. Cardiovasc. Surg. 150, 377\u2013385.e2 (2015).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"1084_CR190","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.21873\/anticanres.16516","volume":"43","author":"A Pratap","year":"2023","unstructured":"Pratap, A. et al. Targeting glypican-1 reverses resistance to 5-fluorouracil in esophageal adenocarcinoma cells. Anticancer Res. 43, 3411\u20133418 (2023).","journal-title":"Anticancer Res."},{"key":"1084_CR191","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1073\/pnas.1820459116","volume":"116","author":"EA Ebbing","year":"2019","unstructured":"Ebbing, E. A. et al. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. Proc. Natl Acad. Sci. USA 116, 2237\u20132242 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1084_CR192","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/SLA.0000000000001928","volume":"264","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. miR-221 mediates chemoresistance of esophageal adenocarcinoma by direct targeting of DKK2 expression. Ann. Surg. 264, 804\u2013814 (2016).","journal-title":"Ann. Surg."},{"key":"1084_CR193","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/jnci\/djac024","volume":"114","author":"TE Jabbour","year":"2022","unstructured":"Jabbour, T. E. et al. ATM germline-mutated gastroesophageal junction adenocarcinomas: clinical descriptors, molecular characteristics, and potential therapeutic implications. J. Natl Cancer Inst. 114, 761\u2013770 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"1084_CR194","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1259\/0007-1285-26-312-638","volume":"26","author":"LH Gray","year":"1953","unstructured":"Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S. & Scott, O. C. A. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26, 638\u2013648 (1953).","journal-title":"Br. J. Radiol."},{"key":"1084_CR195","doi-asserted-by":"publisher","first-page":"11400","DOI":"10.18632\/oncotarget.13940","volume":"8","author":"N Lynam-Lennon","year":"2016","unstructured":"Lynam-Lennon, N. et al. MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype. Oncotarget 8, 11400\u201311413 (2016).","journal-title":"Oncotarget"},{"key":"1084_CR196","first-page":"100376","volume":"27","author":"S Marcone","year":"2021","unstructured":"Marcone, S. et al. Proteomic signatures of radioresistance: alteration of inflammation, angiogenesis and metabolism-related factors in radioresistant oesophageal adenocarcinoma. Cancer Treat. Res. Commun. 27, 100376 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"key":"1084_CR197","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","volume":"391","author":"T Leong","year":"2024","unstructured":"Leong, T. et al. Preoperative chemoradiotherapy for resectable gastric cancer. N. Engl. J. Med. 391, 1810\u20131821 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR198","first-page":"410","volume":"42","author":"S-E Al-Batran","year":"2024","unstructured":"Al-Batran, S.-E. et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. J. Clin. Oncol. 42, 410\u2013420 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR199","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian, Y. Y. et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N. Engl. J. Med. 393, 217\u2013230 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR200","doi-asserted-by":"publisher","first-page":"TPS4184","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4184","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen, S. et al. A randomized, open-label phase II\/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633\/DANTE trial, a trial of AIO in collaboration with SAKK. J. Clin. Oncol. 42, TPS4184 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR201","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 25, 212\u2013224 (2024).","journal-title":"Lancet Oncol."},{"key":"1084_CR202","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","volume":"30","author":"YL Verschoor","year":"2024","unstructured":"Verschoor, Y. L. et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nat. Med. 30, 519\u2013530 (2024).","journal-title":"Nat. Med."},{"key":"1084_CR203","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1158\/1078-0432.CCR-20-4443","volume":"27","author":"T van den Ende","year":"2021","unstructured":"van den Ende, T. et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). Clin. Cancer Res. 27, 3351\u20133359 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR204","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","volume":"36","author":"A Raimondi","year":"2025","unstructured":"Raimondi, A. et al. Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. Ann. Oncol. 36, 285\u2013296 (2025).","journal-title":"Ann. Oncol."},{"key":"1084_CR205","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2022","unstructured":"Andr\u00e9, T. et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J. Clin. Oncol. 41, 255\u2013265 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR206","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","volume":"36","author":"F Lordick","year":"2025","unstructured":"Lordick, F. et al. Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and\/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. Ann. Oncol. 36, 197\u2013207 (2025).","journal-title":"Ann. Oncol."},{"key":"1084_CR207","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6, 1571\u20131580 (2020).","journal-title":"JAMA Oncol."},{"key":"1084_CR208","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun, J.-M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759\u2013771 (2021).","journal-title":"Lancet"},{"key":"1084_CR209","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"key":"1084_CR210","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian, Y. Y. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 402, 2197\u20132208 (2023).","journal-title":"Lancet"},{"key":"1084_CR211","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"M-Z Qiu","year":"2024","unstructured":"Qiu, M.-Z. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 385, e078876 (2024).","journal-title":"BMJ"},{"key":"1084_CR212","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer. JAMA 330, 2064\u20132074 (2023).","journal-title":"JAMA"},{"key":"1084_CR213","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"1084_CR214","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","volume":"36","author":"YY Janjigian","year":"2018","unstructured":"Janjigian, Y. Y. et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J. Clin. Oncol. 36, 2836\u20132844 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR215","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1200\/JCO.20.00892","volume":"39","author":"M Moehler","year":"2020","unstructured":"Moehler, M. et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J. Clin. Oncol. 39, 966\u2013977 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR216","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","volume":"35","author":"J-S Frenel","year":"2017","unstructured":"Frenel, J.-S. et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J. Clin. Oncol. 35, 4035\u20134041 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR217","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs, C. S. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 4, e180013 (2018).","journal-title":"JAMA Oncol."},{"key":"1084_CR218","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs, C. S. et al. Pembrolizumab in advanced gastric and gastroesophageal junction cancer. JAMA Oncol. 4, e180013 (2018).","journal-title":"JAMA Oncol."},{"key":"1084_CR219","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","volume":"25","author":"CS Fuchs","year":"2021","unstructured":"Fuchs, C. S. et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer 25, 197\u2013206 (2021).","journal-title":"Gastric Cancer"},{"key":"1084_CR220","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392, 123\u2013133 (2018).","journal-title":"Lancet"},{"key":"1084_CR221","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","volume":"5","author":"MA Shah","year":"2018","unstructured":"Shah, M. A. et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 5, 546 (2018).","journal-title":"JAMA Oncol."},{"key":"1084_CR222","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima, T. et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38, 4138\u20134148 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR223","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang, Y.-K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471 (2017).","journal-title":"Lancet"},{"key":"1084_CR224","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","volume":"29","author":"Y-J Bang","year":"2018","unstructured":"Bang, Y.-J. et al. Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann. Oncol. 29, 2052\u20132060 (2018).","journal-title":"Ann. Oncol."},{"key":"1084_CR225","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejca.2018.02.014","volume":"94","author":"L Hewitt","year":"2018","unstructured":"Hewitt, L. et al. Epstein\u2013Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: a large multi-centre study. Eur. J. Cancer 94, 104\u2013114 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1084_CR226","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"1084_CR227","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR228","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara, K. et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch. Pathol. Lab. Med. 143, 330\u2013337 (2019).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"1084_CR229","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(20)30326-0","volume":"21","author":"DVT Catenacci","year":"2020","unstructured":"Catenacci, D. V. T. et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22\u201305): a single-arm, phase 1b\u20132 trial. Lancet Oncol. 21, 1066\u20131076 (2020).","journal-title":"Lancet Oncol."},{"key":"1084_CR230","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727\u2013730 (2021).","journal-title":"Nature"},{"key":"1084_CR231","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1200\/JCO.24.00410","volume":"43","author":"SJ Klempner","year":"2024","unstructured":"Klempner, S. J. et al. DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy in advanced gastric or gastroesophageal junction adenocarcinoma: DisTinGuish. J. Clin. Oncol. 43, 339\u2013349 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR232","doi-asserted-by":"publisher","first-page":"102045","DOI":"10.1016\/j.xcrm.2025.102045","volume":"6","author":"T Alcindor","year":"2025","unstructured":"Alcindor, T. et al. Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: the role of M2 macrophage landscape in predicting response. Cell Rep. Med. 6, 102045 (2025).","journal-title":"Cell Rep. Med."},{"key":"1084_CR233","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.18632\/oncotarget.27052","volume":"10","author":"L Babar","year":"2019","unstructured":"Babar, L. et al. Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma. Oncotarget 10, 4546\u20134555 (2019).","journal-title":"Oncotarget"},{"key":"1084_CR234","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly, R. J. et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat. Med. 30, 1023\u20131034 (2024).","journal-title":"Nat. Med."},{"key":"1084_CR235","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/SLA.0000000000002410","volume":"268","author":"RJ Kelly","year":"2018","unstructured":"Kelly, R. J. et al. The dynamic and transient immune microenvironment in locally advanced esophageal adenocarcinoma post chemoradiation. Ann. Surg. 268, 992\u2013999 (2018).","journal-title":"Ann. Surg."},{"key":"1084_CR236","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","volume":"34","author":"JR Hecht","year":"2016","unstructured":"Hecht, J. R. et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC \u2014 a randomized phase III trial. J. Clin. Oncol. 34, 443\u2013451 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR237","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","volume":"19","author":"J Tabernero","year":"2018","unstructured":"Tabernero, J. et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 19, 1372\u20131384 (2018).","journal-title":"Lancet Oncol."},{"key":"1084_CR238","doi-asserted-by":"publisher","first-page":"100563","DOI":"10.1016\/j.esmoop.2022.100563","volume":"7","author":"DVT Catenacci","year":"2022","unstructured":"Catenacci, D. V. T. et al. Margetuximab with retifanlimab as first-line therapy in HER2+\/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open 7, 100563 (2022).","journal-title":"ESMO Open"},{"key":"1084_CR239","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N. Engl. J. Med. 393, 336\u2013348 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR240","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","volume":"14","author":"T Waddell","year":"2013","unstructured":"Waddell, T. et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 481\u2013489 (2013).","journal-title":"Lancet Oncol."},{"key":"1084_CR241","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(17)30566-1","volume":"18","author":"DVT Catenacci","year":"2017","unstructured":"Catenacci, D. V. T. et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1467\u20131482 (2017).","journal-title":"Lancet Oncol."},{"key":"1084_CR242","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamaoncol.2016.5580","volume":"3","author":"MA Shah","year":"2017","unstructured":"Shah, M. A. et al. Adding onartuzumab to chemotherapy for gastroesophageal adenocarcinoma. JAMA Oncol. 3, 620\u2013627 (2017).","journal-title":"JAMA Oncol."},{"key":"1084_CR243","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","volume":"20","author":"CS Fuchs","year":"2019","unstructured":"Fuchs, C. S. et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 420\u2013435 (2019).","journal-title":"Lancet Oncol."},{"key":"1084_CR244","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"1084_CR245","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"1084_CR246","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","volume":"27","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg, Z. A. et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer 27, 558\u2013570 (2024).","journal-title":"Gastric Cancer"},{"key":"1084_CR247","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","volume":"21","author":"YY Janjigian","year":"2020","unstructured":"Janjigian, Y. Y. et al. First-line pembrolizumab and trastuzumab in HER2-positive esophagogastric cancer. Lancet Oncol. 21, 821\u2013831 (2020).","journal-title":"Lancet Oncol."},{"key":"1084_CR248","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/bjc.2015.440","volume":"114","author":"NC Tebbutt","year":"2016","unstructured":"Tebbutt, N. C. et al. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. Br. J. Cancer 114, 505\u2013509 (2016).","journal-title":"Br. J. Cancer"},{"key":"1084_CR249","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/bjc.2011.280","volume":"105","author":"ZA Wainberg","year":"2011","unstructured":"Wainberg, Z. A. et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br. J. Cancer 105, 760\u2013765 (2011).","journal-title":"Br. J. Cancer"},{"key":"1084_CR250","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/cncr.32029","volume":"125","author":"JM Cleary","year":"2019","unstructured":"Cleary, J. M. et al. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: a double-blind, randomized, multicenter phase 2 trial. Cancer 125, 2213\u20132221 (2019).","journal-title":"Cancer"},{"key":"1084_CR251","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/annonc\/mdw423","volume":"27","author":"H Yoon","year":"2019","unstructured":"Yoon, H. et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter phase II trial. Ann. Oncol. 27, 2196\u20132203 (2019).","journal-title":"Ann. Oncol."},{"key":"1084_CR252","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2019.04.020","volume":"115","author":"D Malka","year":"2019","unstructured":"Malka, D. et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur. J. Cancer 115, 97\u2013106 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1084_CR253","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/07357907.2017.1337782","volume":"35","author":"S Pant","year":"2017","unstructured":"Pant, S. et al. A phase II study of the c-Met inhibitor tivantinib in combination with FOLFOX for the treatment of patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal junction, or stomach. Cancer Invest. 35, 463\u2013472 (2017).","journal-title":"Cancer Invest."},{"key":"1084_CR254","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/annonc\/mds502","volume":"24","author":"MM Eatock","year":"2013","unstructured":"Eatock, M. M. et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann. Oncol. 24, 710\u2013718 (2013).","journal-title":"Ann. Oncol."},{"key":"1084_CR255","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience, P. C. et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 18, 640\u2013653 (2017).","journal-title":"Lancet Oncol."},{"key":"1084_CR256","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419\u20132430 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR257","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine 68, 102415 (2024).","journal-title":"EClinicalMedicine"},{"key":"1084_CR258","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","volume":"15","author":"SJ Dutton","year":"2014","unstructured":"Dutton, S. J. et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 15, 894\u2013904 (2014).","journal-title":"Lancet Oncol."},{"key":"1084_CR259","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1634\/theoncologist.2017-0657","volume":"23","author":"H Yoon","year":"2018","unstructured":"Yoon, H. et al. Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma. Oncologist 23, 1004\u2013e102 (2018).","journal-title":"Oncologist"},{"key":"1084_CR260","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/annonc\/mdq604","volume":"22","author":"JA Chan","year":"2011","unstructured":"Chan, J. A. et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann. Oncol. 22, 1367\u20131373 (2011).","journal-title":"Ann. Oncol."},{"key":"1084_CR261","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1097\/JTO.0b013e3181e77a92","volume":"5","author":"PJ Gold","year":"2010","unstructured":"Gold, P. J. et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J. Thorac. Oncol. 5, 1472\u20131476 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"1084_CR262","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31\u201339 (2014).","journal-title":"Lancet"},{"key":"1084_CR263","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u20131235 (2014).","journal-title":"Lancet Oncol."},{"key":"1084_CR264","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134731","volume":"10","author":"YY Janjigian","year":"2015","unstructured":"Janjigian, Y. Y. et al. Phase II trial of sorafenib in patients with chemotherapy refractory metastatic esophageal and gastroesophageal (GE) junction cancer. PLoS ONE 10, e0134731 (2015).","journal-title":"PLoS ONE"},{"key":"1084_CR265","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-21-4021","volume":"28","author":"MA Shah","year":"2022","unstructured":"Shah, M. A. et al. Randomized, double-blind, placebo-controlled phase III study of paclitaxel \u00b1 napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. Clin. Cancer Res. 28, 3686\u20133694 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR266","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci, O. et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann. Oncol. 30, 1487\u20131495 (2019).","journal-title":"Ann. Oncol."},{"key":"1084_CR267","doi-asserted-by":"publisher","first-page":"e1864","DOI":"10.1634\/theoncologist.2020-0681","volume":"25","author":"TB Karasic","year":"2020","unstructured":"Karasic, T. B. et al. Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer. Oncologist 25, e1864\u2013e1868 (2020).","journal-title":"Oncologist"},{"key":"1084_CR268","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s10637-019-00889-y","volume":"38","author":"L Goyal","year":"2020","unstructured":"Goyal, L. et al. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Invest. New Drugs 38, 1533\u20131539 (2020).","journal-title":"Invest. New Drugs"},{"key":"1084_CR269","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00280-015-2744-5","volume":"76","author":"ZA Wainberg","year":"2015","unstructured":"Wainberg, Z. A. et al. Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemother. Pharmacol. 76, 61\u201367 (2015).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1084_CR270","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"0","author":"C Qi","year":"2025","unstructured":"Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet 0, 2049\u20132060 (2025).","journal-title":"Lancet"},{"key":"1084_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-12337-4","volume":"15","author":"S Pak","year":"2025","unstructured":"Pak, S. et al. The expression of the tight junction protein and therapeutical target Claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma. Sci. Rep. 15, 28958 (2025).","journal-title":"Sci. Rep."},{"key":"1084_CR272","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","volume":"25","author":"SB Maron","year":"2019","unstructured":"Maron, S. B. et al. Circulating tumor DNA sequencing of gastroesophageal adenocarcinoma. Clin. Cancer Res. 25, 7098\u20137112 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1084_CR273","doi-asserted-by":"publisher","first-page":"102418","DOI":"10.1016\/j.ctrv.2022.102418","volume":"108","author":"D Blang\u00e9","year":"2022","unstructured":"Blang\u00e9, D., Stroes, C. I., Derks, S., Bijlsma, M. F. & van Laarhoven, H. W. M. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: a systematic review. Cancer Treat. Rev. 108, 102418 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"1084_CR274","doi-asserted-by":"publisher","first-page":"101664","DOI":"10.1016\/j.eclinm.2022.101664","volume":"53","author":"CM Jones","year":"2022","unstructured":"Jones, C. M. et al. Use of a non-endoscopic immunocytological device (Cytosponge\u2122) for post chemoradiotherapy surveillance in patients with oesophageal cancer in the UK (CYTOFLOC): a multicentre feasibility study. EClinicalMedicine 53, 101664 (2022).","journal-title":"EClinicalMedicine"},{"key":"1084_CR275","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-20-1408","volume":"11","author":"DV Catenacci","year":"2020","unstructured":"Catenacci, D. V. et al. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 11, 308\u2013325 (2020).","journal-title":"Cancer Discov."},{"key":"1084_CR276","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2025.43.4_suppl.448","volume":"43","author":"YY Janjigian","year":"2025","unstructured":"Janjigian, Y. Y. et al. Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg\/kg triplet combination of DESTINY-Gastric03 (DG-03): first-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced\/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA). J. Clin. Oncol. 43, 448 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR277","first-page":"TPS4204","volume":"43","author":"RH Xu","year":"2025","unstructured":"Xu, R. H. et al. ARTEMIDE-Gastric01: a phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC\/GEJC). J. Clin. Oncol. 43, TPS4204 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR278","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07388-x","volume":"20","author":"S Lorenzen","year":"2020","unstructured":"Lorenzen, S. et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction \u2014 a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 20, 886 (2020).","journal-title":"BMC Cancer"},{"key":"1084_CR279","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5728-8","volume":"19","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer 19, 606 (2019).","journal-title":"BMC Cancer"},{"key":"1084_CR280","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02440-5","volume":"22","author":"J Shi","year":"2024","unstructured":"Shi, J. et al. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial. BMC Gastroenterol. 22, 359 (2024).","journal-title":"BMC Gastroenterol."},{"key":"1084_CR281","doi-asserted-by":"publisher","first-page":"100934","DOI":"10.1016\/j.conctc.2022.100934","volume":"28","author":"CJ van der Zijden","year":"2022","unstructured":"van der Zijden, C. J. et al. Chemotherapy and chemoradiotherapy for adenocarcinoma of the oesophagus and esophagogastric junction with oligometastases: protocol of the TNT-OES-1 trial. Contemp. Clin. Trials Commun. 28, 100934 (2022).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"1084_CR282","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4770-2","volume":"18","author":"AE Slagter","year":"2018","unstructured":"Slagter, A. E. et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 18, 877 (2018).","journal-title":"BMC Cancer"},{"key":"1084_CR283","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clon.2024.03.020","volume":"36","author":"C Sanghera","year":"2024","unstructured":"Sanghera, C., McClurg, D. P. & Jones, C. M. Systematic review of hypofractionated radiation therapy for the treatment of oesophageal squamous cell carcinoma and oesophageal adenocarcinoma. Clin. Oncol. 36, 430\u2013444 (2024).","journal-title":"Clin. Oncol."},{"key":"1084_CR284","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.radonc.2006.01.009","volume":"78","author":"JI Geh","year":"2006","unstructured":"Geh, J. I., Bond, S. J., Bentzen, S. M. & Glynne-Jones, R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother. Oncol. 78, 236\u2013244 (2006).","journal-title":"Radiother. Oncol."},{"key":"1084_CR285","doi-asserted-by":"publisher","first-page":"102059","DOI":"10.1016\/j.eclinm.2023.102059","volume":"61","author":"S Mukherjee","year":"2023","unstructured":"Mukherjee, S. et al. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61, 102059 (2023).","journal-title":"EClinicalMedicine"},{"key":"1084_CR286","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2967\/jnumed.110.085803","volume":"52","author":"CM zum B\u00fcschenfelde","year":"2011","unstructured":"zum B\u00fcschenfelde, C. M. et al. 18F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II trial. J. Nucl. Med. 52, 1189\u20131196 (2011).","journal-title":"J. Nucl. Med."},{"key":"1084_CR287","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","volume":"8","author":"F Lordick","year":"2007","unstructured":"Lordick, F. et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 8, 797\u2013805 (2007).","journal-title":"Lancet Oncol."},{"key":"1084_CR288","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1200\/JCO.2006.06.7801","volume":"24","author":"K Ott","year":"2006","unstructured":"Ott, K. et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J. Clin. Oncol. 24, 4692\u20134698 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR289","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1200\/JCO.2001.19.12.3058","volume":"19","author":"WA Weber","year":"2001","unstructured":"Weber, W. A. et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 19, 3058\u20133065 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR290","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15596-z","volume":"11","author":"A Acar","year":"2020","unstructured":"Acar, A. et al. Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nat. Commun. 11, 1923 (2020).","journal-title":"Nat. Commun."},{"key":"1084_CR291","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198347","volume":"13","author":"M Kim","year":"2018","unstructured":"Kim, M. et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS ONE 13, e0198347 (2018).","journal-title":"PLoS ONE"},{"key":"1084_CR292","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1200\/JCO.2023.41.16_suppl.4034","volume":"41","author":"T Luo","year":"2023","unstructured":"Luo, T. et al. EpCAM CAR T (IMC001) for the treatment of advanced GI cancers. J. Clin. Oncol. 41, 4034\u20134034 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1084_CR293","doi-asserted-by":"publisher","first-page":"25080","DOI":"10.18632\/oncotarget.15340","volume":"8","author":"MA Butt","year":"2017","unstructured":"Butt, M. A. et al. Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody\u2013drug conjugate. Oncotarget 8, 25080\u201325096 (2017).","journal-title":"Oncotarget"},{"key":"1084_CR294","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1245\/s10434-024-15570-9","volume":"31","author":"KE Cox","year":"2024","unstructured":"Cox, K. E. et al. Targeting patient-derived orthotopic gastric cancers with a fluorescent humanized anti-CEA antibody. Ann. Surg. Oncol. 31, 6291\u20136299 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"1084_CR295","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J. Clin. Oncol. 42, 2012\u20132020 (2024).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01084-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:04:44Z","timestamp":1765537484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01084-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":295,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01084-0","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"14 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.C.F. developed the capsule sponge technology and associated patents, which were licensed to Covidien (now Medtronic) by the UK Medical Research Council; is a shareholder in Cyted Health; is a member of the advisory board for AstraZeneca and the CRUK Functional Genomics Centre; and has acted as a consultant for AstraZeneca and 23andMe. C.M.J. has acted as a consultant for Candesic outside of the scope of the current manuscript. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}